Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, ...

The Pt Deendayal Upadhyay Memorial Health Sciences and Ayush University collaborates with CSIR-CCMB to enhance sickle cell anemia diagnosis and genetic research, improving public health outcomes in ...

On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...

Ghana on Tuesday unveiled a National Sickle Cell Disease (SCD) Strategy aimed at improving both preventive and treatment services for the condition.

Sickle cell anemia requires ongoing ... Hydroxyurea causes the body to produce fetal hemoglobin, a type of hemoglobin that is normally produced only before and shortly after birth.

Ghana on Tuesday unveiled a National Sickle Cell Disease (SCD) Strategy aimed at improving both preventive and treatment services for the condition.

Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Anemia is defined as a condition in which the hemoglobin (Hb ... and heminoglobinopathies, including sickle cell disease and glucose-6-phosphate dehydrogenase (G6PD) deficiency.

TDT and SCD are caused by two mutations affecting a key component of hemoglobin, the oxygen-carrying molecule ... transfusion-dependent beta-thalassemia and sickle-cell anemia. Casgevy received ...

BEAM-101, a gene-editing stem cell therapy, showed early signs of efficacy among the first treated sickle cell patients in a ...

Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all ...